Multi Medika (Indonesia) Performance
| MMIX Stock | 97.00 1.00 1.04% |
On a scale of 0 to 100, Multi Medika holds a performance score of 3. The company secures a Beta (Market Risk) of 2.78, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Multi Medika will likely underperform. Please check Multi Medika's standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Multi Medika's current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Multi Medika Internasional are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting forward-looking signals, Multi Medika disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Multi |
Multi Medika Relative Risk vs. Return Landscape
If you would invest 9,700 in Multi Medika Internasional on December 27, 2024 and sell it today you would earn a total of 0.00 from holding Multi Medika Internasional or generate 0.0% return on investment over 90 days. Multi Medika Internasional is generating 0.5568% of daily returns and assumes 11.0783% volatility on return distribution over the 90 days horizon. Simply put, 98% of stocks are less volatile than Multi, and 89% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Multi Medika Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Multi Medika's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Multi Medika Internasional, and traders can use it to determine the average amount a Multi Medika's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0503
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MMIX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.08 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.56 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Multi Medika is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Multi Medika by adding it to a well-diversified portfolio.
Multi Medika Fundamentals Growth
Multi Stock prices reflect investors' perceptions of the future prospects and financial health of Multi Medika, and Multi Medika fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Multi Stock performance.
| Return On Equity | 1.81 | |||
| Return On Asset | 0.37 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.18 % | |||
| Price To Sales | 3.41 X | |||
| Revenue | 181.84 B | |||
| EBITDA | 33.57 B | |||
| Book Value Per Share | 27.86 X | |||
About Multi Medika Performance
By examining Multi Medika's fundamental ratios, stakeholders can obtain critical insights into Multi Medika's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Multi Medika is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about Multi Medika Interna performance evaluation
Checking the ongoing alerts about Multi Medika for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Multi Medika Interna help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Multi Medika Interna is way too risky over 90 days horizon | |
| Multi Medika Interna appears to be risky and price may revert if volatility continues |
- Analyzing Multi Medika's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Multi Medika's stock is overvalued or undervalued compared to its peers.
- Examining Multi Medika's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Multi Medika's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Multi Medika's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Multi Medika's stock. These opinions can provide insight into Multi Medika's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Multi Stock
Multi Medika financial ratios help investors to determine whether Multi Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Multi with respect to the benefits of owning Multi Medika security.